The molecular mechanisms described above—oxidative stress, mitochondrial dysfunction, inflammation, and NO dysregulation—not only contribute to the progression of DCM in experimental models but are also reflected in clinical studies of ALDH2*2 carriers. This evidence concerns the gene ALDH2 and familial dilated cardiomyopathy.